✦ LIBER ✦

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Scribed by Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark S. Shahin; Xun C. Zhou; Robert S. Mannel; Harsh B. Pathak; Wei Hu; R. Katherine Alpaugh; Anil K. Sood; Andrew K. Godwin

Book ID: 118506669
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 205 KB
Volume: 127
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2012.06.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of lapatinib in th

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB

A phase II study of vorinostat in the tr

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB

A phase II evaluation of mifepristone in

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

A phase II evaluation of AMG 102 (rilotu

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Martin, Lainie P.; Sill, Michael; Shahin, Mark S.; Powell, Matthew; DiSilvestro, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 246 KB

Phase II Trial of Bevacizumab in Persist

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

✍ Burger, R. A.; Sill, M. W.; Monk, B. J.; Greer, B. E.; Sorosky, J. I. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 112 KB

A phase II study of a urokinase-derived

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Michael A. Gold; William E. Brady; Heather A. Lankes; Peter G. Rose; Joseph L. K 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 257 KB